Literature DB >> 15964135

The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results.

Arnold Melman1, Natan Bar-Chama, Andrew McCullough, Kelvin Davies, George Christ.   

Abstract

OBJECTIVE: To test the safety of a single intracavernous injection of a plasmid vector (hMaxi-K) that expresses the hSlo gene, that encodes the alpha-subunit of the Maxi-K channel, for the treatment of erectile dysfunction (ED).
METHODS: Six men, thus far have fulfilled the entry criteria of the protocol and had gene transfer with hMaxi-K. Three received a dose of 500 microg and three received a dose 1000 microg of the gene product, injected intracavernously as naked DNA. Dosing at 5000 microg and higher is planned.
RESULTS: The primary end point of the phase I trial is safety. No drug-related adverse events or significant laboratory changes have occurred after the gene transfer. Moreover, there is no evidence of the gene in semen at the one copy per mug total DNA in any of the participants.
CONCLUSION: Preliminary results indicate that, in a single dose escalation study, ion channel gene transfer with hMaxi-K can be administered safely to men with ED without adverse events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964135     DOI: 10.1016/j.eururo.2005.05.005

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

Review 1.  Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction.

Authors:  George J Christ; Steve Hodges
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

2.  Vcsa1 acts as a marker of erectile function recovery after gene therapeutic and pharmacological interventions.

Authors:  Giulia Calenda; Yuehong Tong; Moses Tar; Daniel Lowe; Joseph Siragusa; Arnold Melman; Kelvin P Davies
Journal:  J Urol       Date:  2009-04-17       Impact factor: 7.450

3.  Variable coding sequence protein A1 as a marker for erectile dysfunction.

Authors:  Yuehong Tong; Moses Tar; Felix Davelman; George Christ; Arnold Melman; Kelvin P Davies
Journal:  BJU Int       Date:  2006-08       Impact factor: 5.588

4.  Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat.

Authors:  Kelvin P Davies; Moses Tar; Catherine Rougeot; Arnold Melman
Journal:  BJU Int       Date:  2006-10-09       Impact factor: 5.588

Review 5.  Emerging tools for erectile dysfunction: a role for regenerative medicine.

Authors:  Lukman Hakim; Frank Van der Aa; Trinity J Bivalacqua; Petter Hedlund; Maarten Albersen
Journal:  Nat Rev Urol       Date:  2012-07-24       Impact factor: 14.432

6.  Silencing MaxiK activity in corporal smooth muscle cells initiates compensatory mechanisms to maintain calcium homeostasis.

Authors:  Giulia Calenda; Sylvia Ottilie Suadicani; Rodolfo Iglesias; David Conover Spray; Arnold Melman; Kelvin Paul Davies
Journal:  J Sex Med       Date:  2011-01-26       Impact factor: 3.802

7.  Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury.

Authors:  R Kato; D Wolfe; C H Coyle; J B Wechuck; P Tyagi; T Tsukamoto; J B Nelson; J C Glorioso; M B Chancellor; N Yoshimura
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

Review 8.  Erection rehabilitation following prostatectomy--current strategies and future directions.

Authors:  Nikolai A Sopko; Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2016-03-15       Impact factor: 14.432

9.  Ageing causes cytoplasmic retention of MaxiK channels in rat corporal smooth muscle cells.

Authors:  K P Davies; Y Stanevsky; M T Tar; T Moses; J S Chang; M R Chance; A Melman
Journal:  Int J Impot Res       Date:  2007-02-08       Impact factor: 2.896

Review 10.  Erectile dysfunction.

Authors:  Faysal A Yafi; Lawrence Jenkins; Maarten Albersen; Giovanni Corona; Andrea M Isidori; Shari Goldfarb; Mario Maggi; Christian J Nelson; Sharon Parish; Andrea Salonia; Ronny Tan; John P Mulhall; Wayne J G Hellstrom
Journal:  Nat Rev Dis Primers       Date:  2016-02-04       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.